Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(50.0%)
Phase 2
1(25.0%)
Phase 3
1(25.0%)
4Total
Phase 4(2)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01380938Phase 3Completed

Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)

Role: collaborator

NCT01140321Phase 2Completed

Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI

Role: collaborator

NCT00887081Phase 4Unknown

Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies

Role: lead

NCT00733811Phase 4Completed

Efficacy Study of the Use of Sequential DFP-DFO Versus DFP

Role: lead

All 4 trials loaded